
Compare sexual changes with fatigue and low mood as possible low testosterone symptoms, and learn how clinicians weigh symptoms alongside blood tests.

Sexual changes and general complaints such as fatigue carry different clinical weight when doctors assess whether testosterone deficiency may explain a man's symptoms.
This article is for informational purposes only and is not medical advice. Personal decisions about hormone testing or treatment belong with a qualified clinician.
The European Association of Urology (EAU) identifies reduced libido, erectile dysfunction and fewer spontaneous or morning erections as the sexual symptoms most specific to late-onset hypogonadism. This is the form of testosterone deficiency addressed by the guideline's discussion of symptoms arising later in life.
These symptoms have a particular medical use: they help clinicians identify a pattern that deserves consideration during a testosterone assessment. Their value lies in their closer association with the condition compared with more general complaints.
The EAU highlights three aspects of sexual function:
Keeping these observations separate makes a symptom history more precise. A description of changed desire communicates something different from a description of changed erections. Combining everything into a general statement that sexual function has declined leaves less detail for the clinical discussion.
The word specific needs careful interpretation. Here it describes the relative usefulness of a symptom as a clue. It does not mean the symptom belongs exclusively to testosterone deficiency. The EAU explicitly cautions that even these symptoms need interpretation alongside the broader clinical picture and biochemical evidence.
That distinction supports a focused conversation rather than a self-diagnosis. Persistent changes in these areas are reasonable reasons to discuss whether testosterone evaluation is appropriate with a qualified clinician.
For a closer look at the differences between these experiences, Testostra's guide to changes in desire and erections provides additional educational context.
The EAU also lists fatigue and low mood among symptoms associated with late-onset hypogonadism. Its symptom table classifies decreased energy as less specific. These complaints therefore have a different role in the assessment from the sexual symptoms highlighted above.
Fatigue describes a concern about energy. Low mood describes a concern about emotional well-being. Unlike the more specific sexual clues, these general complaints give a clinician less direction toward testosterone deficiency when considered on their own.
This is a difference in diagnostic usefulness, not a judgment about how distressing a symptom is. A concern can be important to the person experiencing it while still offering limited information about its cause. The practical response is a broader assessment rather than a stronger assumption about hormones.
The Association of American Medical Colleges (AAMC) reports that the Testosterone Trials found improvements in sexual function, bone density and hemoglobin. Its account describes little or no improvement in energy or cognitive function.
For a reader whose main concern is low energy, that finding matters. The reported benefits were not uniform across all outcomes. Improvement in one area should not be taken as evidence that testosterone treatment will produce the same change in another.
These are treatment findings, not evidence that fatigue identifies testosterone deficiency. They help frame expectations about treatment but do not replace the symptom assessment and blood testing needed to establish a diagnosis.
The practical implication is straightforward: fatigue deserves attention without being assigned a hormonal explanation in advance. The EAU's approach keeps relevant health conditions and medications in the assessment rather than treating low energy as a direct route to testosterone treatment.
The same distinction applies when fatigue occurs alongside sexual changes. Both belong in the history, but they do not acquire equal diagnostic weight simply because they happen together.
The EAU describes diagnosis as requiring compatible symptoms or signs together with biochemical evidence of low testosterone. Doctors therefore weigh the symptom pattern against reliable measurements and the health context in which those measurements were obtained.
The comparison is not a contest in which sexual symptoms automatically win and fatigue gets ignored. It is a way of deciding what each piece of information contributes to the overall assessment.
The EAU recommends reviewing diseases, medications and substances that could interfere with testosterone production or action. This places symptoms within a medical history rather than treating them as isolated clues.
The guideline also identifies obesity, other conditions such as diabetes and overall poor health as major contributors to the prevalence of late-onset hypogonadism with age. These factors belong in the discussion because the hormone question is connected to the person's broader health.
The clinical task is therefore wider than matching a complaint to a symptom list. It includes considering whether a health condition or medication may affect the hormone assessment and how that information fits with the reported changes.
For the reader, the useful distinction is between describing an experience and explaining its cause. “My energy has changed” describes a concern. “Low testosterone is causing it” is a conclusion that requires supporting evidence.
A discussion of medicines and possible hormonal or sexual effects can help frame questions for the clinician reviewing that history. It is not a basis for changing medication independently.
According to the EAU, the recommended evaluation includes morning, fasting total testosterone measurement using a reliable assay. The guideline also recommends repeating testing when an initial result is below its stated threshold.
These requirements make the conditions of measurement part of the interpretation. The question is not only what number appears on the report. It is also whether that number was obtained under appropriate conditions and whether a low result has been confirmed.
The EAU uses 12 nmol/L (3.5 ng/mL) as a threshold it considers reliable for diagnosing late-onset hypogonadism when interpreted alongside symptoms. This is the EAU's stated threshold within its clinical guidance, not a universal cutoff that independently settles every man's diagnosis.
The guideline cautions against testosterone measurement during acute illness. It also notes that non-fasting sampling can affect results. These considerations give clinicians reasons to examine the circumstances of a test before drawing conclusions from it.
A result is most useful when its collection conditions and clinical meaning are clear. Testostra's explanation of test timing and repeat measurements develops this part of the discussion without treating a laboratory number as a diagnosis by itself.
An online questionnaire may seem like a convenient way to combine sexual changes with fatigue or mood concerns. However, the EAU says self-reported questionnaires and structured interviews have poor specificity and should not be used for systematic screening.
A symptom score can make a collection of complaints look more decisive than it is. Adding up answers does not supply the biochemical evidence required by the guideline or resolve the possible contributions of other health conditions.
The useful information is the symptom history itself. A clinician can consider that history together with examination findings where relevant and appropriately collected testosterone results. The score is not a substitute for that process.
The evidence supports questions about both the symptoms and the testing process. Useful topics for a clinical discussion include:
These questions keep the discussion focused on the evidence needed for a clinical decision. They do not assume that every complaint has the same cause or that treatment should follow from a symptom score.
The key distinction is between a reason to investigate and enough evidence to diagnose. More specific sexual changes can strengthen the reason for considering testosterone assessment. Fatigue and low mood broaden the history that needs attention. Reliable testing then helps the clinician judge whether testosterone deficiency is part of the explanation.
Sexual changes provide more specific clues while fatigue and low mood add broader context; both belong alongside reliable testosterone measurements and a clinical assessment.
Deciding which symptoms deserve more weight belongs in clinical care; Testostra handles the separate educational task of explaining the testosterone evidence behind that decision. For men uncertain about fatigue or sexual changes, its articles connect possible low testosterone symptoms with testing and biomarkers to support a better-informed medical discussion without offering a personal diagnosis or treatment plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra